IV immunoglobulins are particularly effective against the cutaneous signs of dermatomyositis

The good results of the international ProDERM trial, evaluating Octagam® intravenous immunoglobulin versus placeboLe placebo est un produit dont la présentation est identique à celle d’un médicament, mais qui ne contient pas de principe actif. Dans un essai clinique, un placebo est utilisé pour mesurer l’action réelle du médicament testé, en comparant les effets du médicament testé contenant le principe actif et ceux du placebo. in 95 adults with dermatomyositis, led to an extension of the indication in 2022. Post-hoc analysis of these data shows that monthly infusions of Octagam® :

• a significant improvement versus placebo in the cutaneous manifestations of the disease (CDASI-A and CDASI-D indexes), regardless of their initial severity,
• a reduction of at least 35% in the CDASI-A score in more than 70% of participants by week 28, a threshold associated with a significant change in quality of life.

Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study. Werth VP, Aggarwal R, Charles-Schoeman C et al. EClinicalMedicine. 2023 Oct 2;64:102234.